Zurich, Switzerland, December 18, 2025 – MUVON Therapeutics, a clinical-stage biotechnology company focused on developing a novel platform for the regeneration of skeletal muscle tissue, announces the appointment of cell therapy pioneer Christine Günther, MD, PhD, as Chief Technology Officer (CTO), effective December 1, 2025. Dr. Günther brings more than 30 years of experience translating regenerative medicine innovations from development to clinical application. Dr. Günther

MUVON is excited to announce that our consortium has been awarded an  Innosuisse  grant, marking a major milestone on our journey to scale out manufacturing and accelerate the path toward a commercial product. Having achieved our positive Phase 2 clinical milestone, we are now concentrating our development efforts on enhanced standardization of the manufacturing process to ensure clinical and commercial scalability and robustness, which is the focus of this Innosuisse grant.

MUVON Therapeutics has been featured by Fierce Biotech  following the release of our positive Phase 2 data. This recognition highlights not only our team’s work, but the growing reality of regenerative medicine at scale—no longer science fiction, but a transformative force in healthcare. Read the full article here .